Format

Send to

Choose Destination
Fertil Steril. 2015 Sep;104(3):715-23.e4. doi: 10.1016/j.fertnstert.2015.06.010. Epub 2015 Jul 4.

Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial.

Author information

1
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna, Vienna, Austria.
2
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
3
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
4
Department of Thoracic Surgery, Otto-Wagner-Spital, Vienna, Austria.
5
Department of Endocrinology and Metabolism, University Clinic of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
6
Academy of Sexual Health, Vienna, Austria.
7
Department of Endocrinology and Metabolism, University Clinic of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Electronic address: michaela.bayerle-eder@meduniwien.ac.at.

Abstract

OBJECTIVE:

To assess the effect of on-demand intranasal oxytocin administration on female sexual function and activity.

DESIGN:

Randomized, prospective, double-blind, placebo-controlled, crossover trial with duration of 22 weeks.

SETTING:

Academic medical center.

PATIENT(S):

Thirty pre-and postmenopausal women with sexual dysfunction.

INTERVENTION(S):

Over 8 weeks, intranasal oxytocin (32 IU) or placebo self-administered by women within 50 minutes before sexual intercourse; after a washout period of 2 weeks, crossover with patients switched to the alternate group for another 8 weeks.

MAIN OUTCOME MEASURE(S):

Primary outcome parameter: Female Sexual Function Index (FSFI); secondary outcome parameters: Female Sexual Distress Scale (FSDS), Sexual Quality of Life-Female (SQOL-F), Sexual Interest and Desire Inventory-Female (SIDI-F), and Hamilton depression scale (HDS).

RESULT(S):

After oxytocin and placebo, the FSFI score increased by 26% and 31%, SQOL-F score by 144% and 125%, and SIDI-F score by 29% and 23%, respectively (repeated measures analysis of variance between groups). After oxytocin and placebo, the FSDS score decreased by 36% and 45%, respectively (repeated measures analysis of variance between groups). There was no statistically significant treatment, sequence (placebo first/second), or interaction effect.

CONCLUSION(S):

Long-term intranasal oxytocin and placebo administration both improved sexual function and symptoms of depression in women over time with no treatment, sequence (placebo first/second), or interaction effect.

CLINICAL TRIAL REGISTRATION NUMBER:

NCT02229721.

KEYWORDS:

Depression; female sexual dysfunction; orgasm; oxytocin; placebo

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center